Latest News Releases From The Newsroom
Potential $463M Contract for Palantir; Potential Upside for Micron, Ford, Chemours and Penumbra
June 05th, 2023
Palantir Technologies Inc. (NYSE: PLTR) has been awarded a significant five-year indefinite-delivery/indefinite-quantity contract with a maximum ceiling of $463,000,000. The contract aims to provide ongoing capabilities and support for select units o. Read more
GitLab Beats Estimates, Bullish Views on Rambus, Meta Platforms, Spotify and Balchem
June 05th, 2023
GitLab Inc. (Nasdaq: GTLB) announced its financial results for the first quarter of fiscal 2024, reporting a loss of $0.06 per share. This figure was better than expected, surpassing the consensus estimate of a loss of $0.14 per share. Looking for. Read more
SEC Files 13 Charges Against Binance Entities and Founder Changpeng Zhao
June 05th, 2023
Charges include operating unregistered exchanges, broker-dealers, and clearing agencies; misrepresenting trading controls and oversight on the Binance.US platform; and the unregistered offer and sale of securities. FOR IMMEDIATE RELEASE 2023-101 . Read more
Stock Updates: Cyclo Therapeutics, Lucy Scientific, Pasithea Therapeutics and Apple Making Waves
June 05th, 2023
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) has entered into a binding agreement with Rafael Holdings, Inc. (NYSE: RFL). Under the agreement, Rafael will acquire 4,000,000 shares of CYTH's common stock, along with warrants to purchase an additio. Read more
Mallinckrodt Under Pressure, Amedisys Offered New Acquisition Bid
June 05th, 2023
Mallinckrodt plc (NYSE American: MNK) has made a significant disclosure in a regulatory filing with the U.S. Securities and Exchange Commission (SEC). The company has received unsolicited letters from various parties holding substantial positions acr. Read more
Foghorn Therapeutics, BiondVax, Bellerophon: Clinical Hold Lifted, Collaboration News, Trial Outcome
June 05th, 2023
Foghorn Therapeutics Inc. (Nasdaq: FHTX) has received positive news from the U.S. Food and Drug Administration (FDA) as the clinical hold on the Phase 1 monotherapy dose escalation study of FHD-286 in acute myelogenous leukemia (AML) and myelodysplas. Read more
Financial Figures Expected: DocuSign, Toro Co, Duckhorn, Planet Labs, FuelCell Energy
June 05th, 2023
On Thursday, June 8, several companies are expected to report their financial results, including: DocuSign, Inc. (Nasdaq: DOCU), a prominent electronic signature and digital transaction management company, is scheduled to release its first quarter. Read more
Verint Systems, Oxford Industries, Semtech, Lovesac, Torrid: Key Date, Earnings Preview
June 05th, 2023
On Wednesday, June 7, several companies are anticipated to release their financial results, including: Verint Systems Inc. (Nasdaq: VRNT), a leading provider of customer engagement solutions, is set to announce its first quarter fiscal 2024 financ. Read more
AstraZeneca, AMSC, Lifecore Biomedical, Arbor Realty Trust: Biotech News, Bullish Perceptions
June 04th, 2023
AstraZeneca's (Nasdaq: AZN) announced that TAGRISSO (osimertinib) has demonstrated a significant improvement in overall survival (OS) in patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).&nb. Read more
Key Upcoming Date: Trip.com, Campbell Soup, GameStop, HashiCorp, Smartsheet, Greif
June 04th, 2023
On Wednesday, June 7, several companies are set to release their financial results, providing insights into their performance and market trends. Trip.com Group Limited (Nasdaq: TCOM), a leading online travel services provider, will announce its fi. Read more
Want To Find Some News?
Recent Posts
-
August 12th, 2025
Earnings Spotlight: Cisco Systems, Brinker, and Coherent on Deck
August 10th, 2025Franco-Nevada, Celanese, and Mercury Systems Earnings Preview
August 09th, 2025
Member Login